Your browser doesn't support javascript.
loading
Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.
Chu, Hongyuan; Zhang, Xinyu; Shi, Jie; Zhou, Zhirui; Yang, Xu.
Affiliation
  • Chu H; Department of Pediatrics, Peking University First Hospital, Beijing, China.
  • Zhang X; Department of Neurology, Peking University First Hospital, Beijing, China.
  • Shi J; Department of Neurology, Tsinghua University Yuquan Hospital, Beijing, 100040, China.
  • Zhou Z; Radiation Oncology Center, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China. zzr3711@163.com.
  • Yang X; Department of Neurology, Peking University Aerospace School of Clinical Medicine (Aerospace Center Hospital), No. 15, Yuquan Road, Haidian District, Beijing, 100049, China. yangxu2011@163.com.
J Neurol ; 270(10): 4713-4728, 2023 Oct.
Article in En | MEDLINE | ID: mdl-37378757
ABSTRACT

OBJECTIVES:

To compare the efficacy and safety of antiseizure medications (ASMs), both as monotherapies and adjunctive therapies, for idiopathic generalized epilepsies (IGEs) and related entities.

METHODS:

Two reviewers independently searched PubMed, Embase, and the Cochrane Library for relevant randomized controlled trials from December 2022 to February 2023. Studies on the efficacy and safety of ASM monotherapies or adjunctive therapies for IGEs and related entities-including juvenile myoclonic epilepsy, childhood absence epilepsy (CAE), juvenile absence epilepsy, or generalized tonic-clonic seizures alone (GTCA)-were included. Efficacy outcomes were the proportions of patients remaining seizure free for 1, 3, 6, and 12 months; safety outcomes were the proportions of any treatment-emergent adverse event (TEAE) and TEAEs leading to discontinuation. Network meta-analyses were performed in a random-effects model to obtain odds ratios and 95% confidence intervals. Rankings of ASMs were based on the surface under the cumulative ranking curve (SUCRA). This study is registered with PROSPERO (No. CRD42022372358).

RESULTS:

Twenty-eight randomized controlled trials containing 4282 patients were included. As monotherapies, all ASMs were more effective than placebo, and valproate and ethosuximide were significantly better than lamotrigine. According to the SUCRA for efficacy, ethosuximide ranked first for CAE, whereas valproate ranked first for other types of IGEs. As adjunctive therapies, topiramate ranked best for GTCA as well as overall for IGEs, while levetiracetam ranked best for myoclonic seizures. For safety, perampanel ranked best (measured by any TEAE).

CONCLUSIONS:

All of the studied ASMs were more effective than placebo. Valproate monotherapy ranked best overall for IGEs, whereas ethosuximide ranked best for CAE. Adjunctive topiramate and levetiracetam were most effective for GTCA and myoclonic seizures, respectively. Furthermore, perampanel had the best tolerability.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Valproic Acid / Epilepsy, Generalized Type of study: Clinical_trials / Systematic_reviews Limits: Child / Humans Language: En Journal: J Neurol Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Valproic Acid / Epilepsy, Generalized Type of study: Clinical_trials / Systematic_reviews Limits: Child / Humans Language: En Journal: J Neurol Year: 2023 Document type: Article Affiliation country: